Breadcrumb AMCP.org Resource Center AMCP submits comments to FDA advocating for clarification of FDAMA Section 114 and the creation of a safe harbor for preapproval information exchange. Tweet this pagePost this page on FacebookPost this page on LinkedInEmail this pagePrint this page 3/17/19 AMCP submits comments to FDA advocating for clarification of FDAMA Section 114 and the creation of a safe harbor for preapproval information exchange. AMCP Comments Re FDA Manufacturer Communications with Payors_FINAL.pdf Tweet this pagePost this page on FacebookPost this page on LinkedInEmail this pagePrint this page